SVB Leerink Weighs in on Theravance Biopharma, Inc.’s Q3 2022 Earnings (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPHGet Rating) – Research analysts at SVB Leerink dropped their Q3 2022 EPS estimates for Theravance Biopharma in a research note issued to investors on Monday, September 19th. SVB Leerink analyst G. Porges now anticipates that the biopharmaceutical company will post earnings of ($0.27) per share for the quarter, down from their prior forecast of ($0.24). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.85) per share. SVB Leerink also issued estimates for Theravance Biopharma’s Q4 2022 earnings at ($0.27) EPS, FY2022 earnings at ($0.99) EPS, Q1 2023 earnings at ($0.42) EPS, Q2 2023 earnings at ($0.21) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at ($0.17) EPS, FY2023 earnings at ($0.93) EPS, FY2024 earnings at ($0.49) EPS and FY2025 earnings at ($0.40) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Theravance Biopharma in a report on Thursday, July 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Theravance Biopharma presently has an average rating of “Hold” and an average price target of $11.75.

Theravance Biopharma Trading Down 0.7 %

NASDAQ TBPH opened at $10.02 on Thursday. The stock’s 50-day moving average price is $9.30 and its two-hundred day moving average price is $9.33. The company has a market cap of $765.80 million, a PE ratio of -7.37 and a beta of 0.66. Theravance Biopharma has a 1 year low of $6.97 and a 1 year high of $13.17.

Theravance Biopharma (NASDAQ:TBPHGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $11.05 million during the quarter, compared to the consensus estimate of $17.47 million. During the same quarter last year, the firm posted ($0.80) earnings per share.

Insider Transactions at Theravance Biopharma

In other news, SVP Richard A. Graham sold 4,906 shares of the stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $9.71, for a total value of $47,637.26. Following the completion of the sale, the senior vice president now directly owns 364,745 shares of the company’s stock, valued at $3,541,673.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Richard A. Graham sold 15,086 shares of the stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $8.79, for a total value of $132,605.94. Following the transaction, the senior vice president now owns 369,651 shares in the company, valued at $3,249,232.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Richard A. Graham sold 4,906 shares of the stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $9.71, for a total value of $47,637.26. Following the completion of the transaction, the senior vice president now owns 364,745 shares in the company, valued at approximately $3,541,673.95. The disclosure for this sale can be found here. 4.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG boosted its position in shares of Theravance Biopharma by 45.0% in the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,101 shares during the period. Quantbot Technologies LP bought a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $62,000. Acadian Asset Management LLC boosted its position in shares of Theravance Biopharma by 51.6% in the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,818 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Theravance Biopharma by 49.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,548 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 2,830 shares during the period. Finally, Principal Financial Group Inc. bought a new stake in shares of Theravance Biopharma in the first quarter valued at approximately $101,000.

About Theravance Biopharma

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Read More

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.